Brief: Prostatype Genomics Q3 EBITDA Stable At SEK 3.6 Mln
Nov 18 (Reuters) - Prostatype Genomics AB PROGEN.ST :
* Q3 NET SALES AMOUNTED TO 426 (556) TSEK
* Q3 EBITDA AMOUNTED TO -3 613 (-3 555) TSEK
* CURRENTLY STUDYING POSSIBILITIES OF COMBINING TWO MODERN
BIOMARKERS INTO WHAT CAN DEVELOP INTO A VERY INTERESTING
OPPORTUNITY
Source text for Eikon: ID:nWkr7bKn65
Further company coverage: PROGEN.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Prostatype Genomics AB
See all newsBrief: Prostatype Genomics Resolves On Rights Issue To Raise About SEK 47.4 Mln
Brief: Prostatype Genomics Intends To Resolve On Rights Issue
Brief: Prostatype Genomics Reports H2 EBITDA Of SEK -17.8 Mln
Brief: Prostatype Genomics Signs Loan Financing Of SEK 10 Million
Brief: Prostatype Genomics Gets SEK 11.5 Mln Through Exercise Of Warrants